The FDA cleared the Triton 1 robotic endoscopy system for diagnostic and therapeutic procedures such as colorectal cancer screening and lesion removal.
Related to this article
The FDA granted fast track designation to the oral pan-KRAS inhibitor KST-6051 for patients with KRAS-mutant advanced or metastatic solid tumors.
The FDA has set a new action date of March 3, 2027, for zanzalintinib/atezolizumab for previously treated metastatic colorectal cancer.
The FDA withdrew accelerated approval for adagrasib/cetuximab in KRAS G12C-mutated colorectal cancer after the KRYSTAL-10 trial failed to improve survival.
Advertisement
Advertisement
Trending on CancerNetwork
1
Japan Approves T-DXd Combo and Dato-DXd for First-Line Metastatic Breast Cancer
2
NICE Recommends T-DXd for HER2-Low Metastatic Breast Cancer
3
Subcutaneous Amivantamab Combo is a “Clear” New Standard in EGFR+ NSCLC
4
FDA Clears Triton Robotic Endoscopy System for Colon Procedures
5